Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $80
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $55 to $80.
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $55 to $80.